SABCS Highlights: Advances in Oral SERD's for Breast Cancer

Name: SABCS Highlights: Advances in Oral SERD's for Breast Cancer
Uploaded: 2026-03-17T00:00:00+00:00
Description: Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs).

Harold Burstein, MD, PhD, and Rinath M. Jeselsohn, MD, discuss the lidERA, evERA, and EMBER-3 trials researching oral selective estrogen receptor degraders (SERDs).

Published

March 17, 2026

Created by

Related Presenters

Harold Burstein, MD, PhD

Medical Oncology

View Full Profile

Rinath Jeselsohn, MD

View full profile